Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 25,758 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 25,758 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $83.30, for a total transaction of $2,145,641.40. Following the sale, the chief operating officer owned 68,052 shares in the company, valued at approximately $5,668,731.60. This trade represents a 27.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock opened at $81.52 on Thursday. The business has a 50-day simple moving average of $79.09 and a 200-day simple moving average of $67.82. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $103.00. The company has a market cap of $6.66 billion, a PE ratio of -22.15 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the prior year, the firm earned ($0.88) EPS. The firm’s revenue was down 60.8% compared to the same quarter last year. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on KYMR shares. BTIG Research cut their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Oppenheimer raised their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Citigroup upped their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Mizuho boosted their price objective on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Finally, HC Wainwright upped their target price on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its stake in Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the period. Osaic Holdings Inc. raised its position in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. raised its position in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.